The story of Sildenafil offers a intricate case study for analysts eyeing pharma. While initial sales were remarkable, present patent lapse and the emergence of cheaper versions have severely impacted earnings. In https://elijahmael455697.slypage.com/41586371/viagra-and-big-pharma-a-dangerous-bet